Beyondspring Pharmaceuticals Inc. literally sprang to life in June 2013 with a phase II cancer compound already in hand. In the second quarter, the company's lead compound, plinabulin, is set to enter a pivotal phase III trial in patients with non-small-cell lung cancer (NSCLC), a notoriously obstinate indication.